Connect with us

Business

Workplace Deaths Drop After States Legalize Medical Marijuana

Published

on

Workers appear to be safer in states that have legalized medical marijuana, according to a new study.

The research, scheduled to be published in the International Journal of Drug Policy in October, is the first of its kind to explore the relationship between medical cannabis laws and workplace fatalities.

Analyzing data from the Bureau of Labor Statistics from 1992 to 2015, a team of researchers found that workplace deaths declined by about 34 percent five years after a state legalized medical cannabis. The trend was most pronounced among workers between the ages of 25 and 44.

“The results provide evidence that legalizing medical marijuana improved workplace safety for workers aged 25–44.”

Because no previous studies have specifically investigated the relationship between legal cannabis and workplace fatalities, the researchers said the results could have gone either way.

Would legalizing cannabis put more workers at risk given the “short-term effects of marijuana use on psychomotor performance and cognition,” or might it lead to fewer workplace deaths in light of what we know about the use of cannabis as a substitute for alcohol and prescription drugs?

Theoretically, if people use marijuana as an alternative to alcohol or pharmaceuticals like opioid-based painkillers, the risk of impairment on the job could be lower, the researchers wrote.

And the data seems to back that up. Though the exact cause behind the trend warrants further research, one finding seems to substantiate the substitution theory: rates of workplace fatalities were lower in states that include pain as a qualifying condition for medical marijuana.

“Specifically, legalizing medical marijuana was associated with a 19.8 percent reduction in the expected number of workplace fatalities among workers aged 25–44 if pain was included as a qualifying condition; if pain was not included as a qualifying condition, the association between legalizing medical marijuana and workplace fatalities was not statistically significant.”

The researchers also observed that states where collective cultivation of cannabis is permitted experienced fewer workplace fatalities, indicating that ease of access may play a role in mitigating these incidents.

Photo courtesy of The International Journal of Drug Policy

How this study could impact public policy

As more states have pushed forward with efforts to legalize cannabis, a conversation has been brewing about employment rights in legal jurisdictions. Courts in numerous states with medical marijuana laws on the books have affirmed employers’ right to terminate workers who test positive for marijuana metabolites, even if they’re registered patients. A handful of states, including Arizona and Illinois, have gone the opposite direction, however, granting employment protections to medical cannabis patients.

More recently, drug reform advocates have been pushing for anti-discrimination policies that would protect marijuana consumers in the workplace. A bill introduced by Rep. Charlie Crist (D-FL) last month would ensure that federal workers wouldn’t be penalized for using cannabis off-the-clock in a legal state, for example.

Part of the logic behind blanket bans on marijuana use is that it is an impairing substance that could jeopardize worker safety. Evidence to support that claim is lacking, and this new study offers a fresh perspective on the debate.

Congressman Pushes Federal Employment Protections For Marijuana Consumers

Photo courtesy of WeedPornDaily.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Los Angeles-based associate editor. His work has also appeared in High Times, VICE and attn.

Business

Square Quietly Launches Program For CBD Cannabis Company Credit Card Processing

Published

on

Companies that sell cannabis products—even those consisting of CBD derived from hemp, which was legalized in the U.S. through the Farm Bill late last year—are continuing to have trouble accessing basic financial services that are available to businesses in other sectors. That includes being able to maintain bank accounts and process their customers’ credit cards.

The latter problem could be solved under a new pilot program that has quietly been launched by the payment processing service Square.

Please visit Forbes to read the rest of this piece.

(Marijuana Moment’s editor provides some content to Forbes via a temporary exclusive publishing license arrangement.)

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Business

Facebook Uses Marijuana And Broccoli To Show Off Its AI Tech

Published

on

Marijuana buds and tempura broccoli can look oddly similar out of context, but Facebook’s artificial intelligence (AI) technology can tell the difference.

At its annual developers conference on Wednesday, Facebook CTO Mike Schroepfer discussed how the social media giant is able to leverage visual AI to spot “policy-violating content,” including advertisements to sell cannabis on the platform. He explained the process by comparing images of the fried vegetable next to marijuana buds, which he described as the “most benign possible example” of prohibited content he could find.

Five years ago, the company relied on “behavioral signals” to catch people advertising cannabis—things like whether the advertiser has been “caught for doing bad stuff before” or whether they used “obvious words” like “marijuana” or “drugs” in the post. But as AI advanced, Facebook developed a system that could visually distinguish cannabis from other miscellaneous items.

To drive the point home, Schroepfer put both images on the screen and challenged the audience to differentiate them.

A few people thought the tempura broccoli was marijuana, but most seemed to get it right. The visual algorithm was 94 percent sure that the marijuana was, in fact, marijuana, and 88 percent sure that the other image was the broccoli.

For Facebook, the technology offers a convenient way to streamline its policy enforcement efforts. But for many cannabis reform groups and media companies that run Facebook accounts, the presentation is a window into an ongoing frustration.

The ban on content promoting the sale of federally illicit drugs has had collateral consequences for pages that post noncommercial marijuana material such as news outlets like Marijuana Moment and state regulatory bodies like the Massachusetts Cannabis Control Commission. These pages have at times been hidden from search results (a technique referred to as “shadowbanning”) because the algorithm isn’t able to accurately differentiate commercial advertisements from cannabis-related news articles, for example.

Marijuana influencers and state-legal cannabis businesses have long complained about having their accounts on the Facebook-owned Instagram platform temporarily disabled or permanently blocked for depicting cannabis or advertising their services.

A policy change may be on the horizon, as the company said in March that it wants “to consider whether we can loosen this restriction, especially in relation to medical marijuana, legal marijuana and brick and mortar stores.” But for the time being, Facebook will continue to enforce the policy, and it hasn’t provided a status update on that front at the conference so far.

“It’s against our policies because it’s against U.S. federal law, so you can’t advertise marijuana on Facebook,” Schroepfer said.

People Searched For A Certain Cannabis Product A Lot In 2018, Google Says

Photo courtesy of Facebook.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Business

FDA Sends Warnings To Three Companies Selling CBD Products

Published

on

At the same time that the Food and Drug Administration (FDA) is working to create a regulatory framework for hemp-derived CBD, it’s also cracking down on companies that are in its view irresponsibly marketing CBD products and making unsanctioned claims about their medical benefits.

FDA announced on Tuesday that it and the Federal Trade Commission sent warning letters to three such companies last month: PotNetwork Holdings in Florida, Nutra Pure in Washington state and Advanced Spine and Pain in New Jersey. The letters were sent “in response to their making unsubstantiated claims related to more than a dozen different products and spanning multiple product webpages, online stores and social media websites,” FDA Commissioner Scott Gottlieb said in a press release.

In a Twitter thread, the commissioner added that he was “concerned to hear recently that several national pharmacy chains and other major retailers have begun to sell or will soon begin to sell” CBD products and that the agency will “be contacting them to remind them of #FDA obligations and our commitment to protect consumers against products that can put them at risk.”

CVS and Walgreens both recently announced they will begin selling CBD-infused products.

In the press release about the warning letters his agency has already sent to CBD companies, Gottlieb asserted that they used their websites to “make unfounded, egregious claims about their products’ ability to limit, treat or cure cancer, neurodegenerative conditions, autoimmune diseases, opioid use disorder, and other serious diseases, without sufficient evidence and the legally required FDA approval.”

FDA is hustling to provide manufacturers guidelines on marketing cannabidiol following the federal legalization of hemp last last year, but the process is complicated by the fact that CBD is the active ingredient in an FDA-approved drug, Epidiolex, and remains the subject of intensive clinical testing. Gottlieb has indicated that it will take years to develop a regulatory plan for CBD without further congressional action.

In the meantime, companies that continue to choose to engage in CBD commerce should be wary about making health claims about their products. The commissioner said FDA has “limited resources” for enforcement operations, but it would take action against companies that make “over-the-line” statements.

In the press announcement, FDA listed some of the unauthorized claims that the three companies made. For example, the products were touted as being able to treat cervical cancer, Alzheimer’s disease and substance use disorder.

“I believe these are egregious, over-the-line claims and we won’t tolerate this kind of deceptive marketing to vulnerable patients,” Gottlieb said. “The FDA continues to be concerned about the proliferation of egregious medical claims being made about products asserting to contain CBD that haven’t been approved by the FDA, such as the products and companies receiving warning letters today.”

“Selling unapproved products with unsubstantiated therapeutic claims can put patients and consumers at risk,” he said. “These products have not been shown to be safe or effective, and deceptive marketing of unproven treatments may keep some patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.”

Questions about what constitutes an unauthorized claim that would put a company at risk of enforcement action will likely come up at the agency’s just-announced public hearing CBD issues on May 31. Stakeholders are invited to submit information about the public safety impacts of CBD and how to manufacture and market products that contain the cannabis compound.

FDA Announces Details On CBD Public Hearing

This piece was updated to include Gottlieb’s tweets about national pharmacy chains.

Photo courtesy of Nicholas C. Morton.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Stay Up To The Moment

Marijuana News In Your Inbox


Support Marijuana Moment

Marijuana News In Your Inbox